Advertisement

Systemic mastocytosis associated with acute myeloid leukemia

  • Frederico Lisboa Nogueira
  • Naira Neves Neto Martins
  • Patrícia Santos Resende Cardoso
  • Mitiko Murao
  • Frederico Henrique Correa de Melo
  • Ana Beatriz Firmato Glória
  • Evandro Maranhão FagundesEmail author
Letter to the Editor

Notes

Compliance with ethical standards

Informed consent was obtained from the patient described in this letter.

References

  1. 1.
    Swerdlow SH, Campo E, Harris NL et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4t. IARC, LyonGoogle Scholar
  2. 2.
    Cornet E, Dumézy F, Roumier C, Lepelley P, Jouy N, Philippe N, Renneville A, Berthon C, Nelken B, Quesnel B, Preudhomme C (2012) Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis. Leuk Res 36:1330–1333.  https://doi.org/10.1016/j.leukres.2012.07.001 CrossRefPubMedGoogle Scholar
  3. 3.
    Pullarkat V, Bedell V, Kim Y, Bhatia R, Nakamura R, Forman S, Sun J, Senitzer D, Slovak ML (2007) Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 31:261–265.  https://doi.org/10.1016/j.leukres.2006.03.006 CrossRefPubMedGoogle Scholar
  4. 4.
    Pardanani A (2018) Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol 94:363–377.  https://doi.org/10.1002/ajh.25371 CrossRefGoogle Scholar
  5. 5.
    Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741–1744.  https://doi.org/10.1182/blood.V99.5.1741 CrossRefPubMedGoogle Scholar
  6. 6.
    Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A (2009) Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 84:790–794.  https://doi.org/10.1002/ajh.21561 CrossRefPubMedGoogle Scholar
  7. 7.
    Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan FT, Hexner E, Mauro MJ, Sternberg DW, Villeneuve M, Huntsman Labed A, Stanek EJ, Hartmann K, Horny HP, Valent P, Reiter A (2016) Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 374:2530–2541.  https://doi.org/10.1056/NEJMoa1513098 CrossRefPubMedGoogle Scholar
  8. 8.
    Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L, Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M, Rodeghiero F, Pizzolo G, Larizza L, Morra E (2006) Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107:3463–3468.  https://doi.org/10.1182/blood-2005-09-3640 CrossRefPubMedGoogle Scholar
  9. 9.
    Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, Lapillonne H, Renneville A, Ragu C, Figeac M, Celli-Lebras K, Lacombe C, Micol JB, Abdel-Wahab O, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C (2016) Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood 127:2451–2459.  https://doi.org/10.1182/blood-2015-12-688705 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Frederico Lisboa Nogueira
    • 1
  • Naira Neves Neto Martins
    • 1
  • Patrícia Santos Resende Cardoso
    • 1
  • Mitiko Murao
    • 1
  • Frederico Henrique Correa de Melo
    • 1
  • Ana Beatriz Firmato Glória
    • 1
  • Evandro Maranhão Fagundes
    • 1
    Email author
  1. 1.Hospital das ClínicasUniversidade Federal de Minas GeraisBelo HorizonteBrazil

Personalised recommendations